Nirmatrelvir/Ritonavir (Paxlovid)

Treatment for COVID-19

Effectiveness
85%
Safety Score
60%
Clinical Trials
45
Participants
15K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
0
Nirmatrelvir/Ritonavir (Paxlovid) Outcomes

for COVID-19

Efficacy Outcomes
Overall Effectiveness
+85%

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
4 active trials recruiting for Nirmatrelvir/Ritonavir (Paxlovid) in COVID-19

A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19

NCT07089680NOT YET RECRUITING
View Study
1.2K participants
OBSERVATIONAL
Started: Aug 18, 2025

A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.

NCT07261085ACTIVE NOT RECRUITING
View Study
99K participants
OBSERVATIONAL
New York, United States
Started: Oct 27, 2025

PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway

NCT05852873ACTIVE NOT RECRUITINGPHASE3
View Study
2K participants
INTERVENTIONAL
Bergen, Norway
Started: May 12, 2023

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

NCT05587894RECRUITINGPHASE2
View Study
256 participants
INTERVENTIONAL
Bordeaux, France +17 more
Started: Apr 27, 2023
Completed Clinical Trials
10 completed trials for Nirmatrelvir/Ritonavir (Paxlovid) in COVID-19

Saliva PCR in Pregnant Women with COVID-19

NCT06735300COMPLETED
View Study
37 participants
OBSERVATIONAL
Tainan, Taiwan
Started: Jun 1, 2022

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

NCT05263908COMPLETED
View Study
3.35K participants
OBSERVATIONAL
Tokyo, Japan
Started: Mar 31, 2022

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.

NCT07090486COMPLETED
View Study
14K participants
OBSERVATIONAL
New York, United States
Started: Apr 15, 2025

A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia

NCT06016556COMPLETED
View Study
250 participants
OBSERVATIONAL
Jeddah, Saudi Arabia +2 more
Started: Oct 17, 2023

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

NCT07072793COMPLETED
View Study
131K participants
OBSERVATIONAL
New York, United States
Started: Oct 31, 2024

Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

NCT05341609COMPLETEDPHASE3
View Study
822 participants
INTERVENTIONAL
Shanghai, China +6 more
Started: Apr 4, 2022

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

NCT06349655COMPLETED
View Study
32.9K participants
OBSERVATIONAL
Zhengzhou, China
Started: Dec 5, 2023

A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

NCT06291831COMPLETED
View Study
3.01K participants
OBSERVATIONAL
Busaiteen, Bahrain
Started: Mar 13, 2024

Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir

NCT05624840COMPLETED
View Study
85 participants
OBSERVATIONAL
Shatin, Hong Kong
Started: Nov 7, 2022

ImPROving Quality of LIFe in the Long COVID Patient

NCT05823896COMPLETEDPHASE2
View Study
219 participants
INTERVENTIONAL
Stockholm, Sweden
Started: May 1, 2023
Showing 20 of 47 total trials